1.60
5.26%
0.08
전일 마감가:
$1.52
열려 있는:
$1.55
하루 거래량:
614.80K
Relative Volume:
1.99
시가총액:
$143.31M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.4665
EPS:
-3.43
순현금흐름:
$-71.16M
1주 성능:
+14.29%
1개월 성능:
+21.21%
6개월 성능:
+22.14%
1년 성능:
+11.89%
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
Immunic Inc Stock (IMUX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2022-09-19 | 재개 | H.C. Wainwright | Buy |
2021-04-15 | 개시 | Aegis Capital | Buy |
2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
2020-10-02 | 개시 | SVB Leerink | Outperform |
2020-08-26 | 개시 | Piper Sandler | Overweight |
2020-08-07 | 재개 | ROTH Capital | Buy |
2020-07-20 | 개시 | BMO Capital Markets | Outperform |
2020-06-05 | 개시 | Wedbush | Outperform |
2020-05-11 | 개시 | H.C. Wainwright | Buy |
2020-03-25 | 개시 | ROTH Capital | Buy |
2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors UK
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors USA
Immunic, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.22) Per Share (NASDAQ:IMUX) - Defense World
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), - Yahoo Finance
Research Analysts Offer Predictions for Immunic, Inc.'s Q3 2024 Earnings (NASDAQ:IMUX) - MarketBeat
Leerink Partnrs Upgrades Immunic (NASDAQ:IMUX) to Strong-Buy - Defense World
Immunic (NASDAQ:IMUX) Upgraded by Leerink Partnrs to "Strong-Buy" - MarketBeat
Immunic’s (IMUX) Outperform Rating Reaffirmed at Leerink Partners - Defense World
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Australia
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com India
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Canada
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Receives $12.75 Consensus Target Price from Analysts - MarketBeat
Immunic (NASDAQ:IMUX) Receives Outperform Rating from Leerink Partners - MarketBeat
Immunic drug targeting post-COVID syndrome in Phase 2 trialICYMI - Proactive financial news
Immunic Welcomes Jason Tardio As COO And President - Contract Pharma
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors Australia
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
Immunic shares hold steady price target, overweight on MS program potential - Investing.com
Immunic shares hold steady price target, overweight on MS program potential - Investing.com India
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - sharewise
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PR Newswire
Immunic extends Executive Chairman's term, raises salary - Investing.com
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com Canada
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 6.3% in August - MarketBeat
There is no doubt that Immunic Inc (IMUX) ticks all the boxes. - SETE News
Immunic Inc (IMUX) shows promising results - US Post News
Immunic, Inc. (NASDAQ:IMUX) Sees Large Decrease in Short Interest - Defense World
Immunic, Inc. (NASDAQ:IMUX) to Post Q3 2024 Earnings of ($0.23) Per Share, B. Riley Forecasts - MarketBeat
Immunic to highlight lead asset’s promise at upcoming Multiple Sclerosis R&D Day - Proactive Investors UK
Market Resilience: Immunic Inc (IMUX) Finishes Weak at 1.40, Down -3.10 - The Dwinnex
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - StockTitan
Immunic initiated with a Buy at B. Riley - TipRanks
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - Yahoo Finance
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com
Immunic (NASDAQ:IMUX) Now Covered by B. Riley - Defense World
B. Riley Initiates Coverage on Immunic (NASDAQ:IMUX) - MarketBeat
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com India
Immunic Inc (IMUX) Stock: A Year of Market Fluctuations - The InvestChronicle
Immunic Stock (NASDAQ:IMUX): CEO Says “Right Time to Buy Now” - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 8.8% in July - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Shares Purchased by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Buys 1,703,047 Shares of Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic, Inc.'s (NASDAQ:IMUX) Shift From Loss To Profit - Simply Wall St
Biotech Alert: Searches spiking for these stocks today - TipRanks
Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Immunic (NASDAQ:IMUX) to Hold - Defense World
Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge - Barchart
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):